pluripotent

Y-27632 dihydrochloride (Y-27632 2HCl) is an orally potent, ATP-competitive inhibitor of ROCK-I and ROCK-II. Y-27632 dihydrochloride also inhibits isolation-induced apoptosis in mouse prostate stem or progenitor cells.

DMH-1 is a potent and selective Bone Morphogenetic Protein (BMP) inhibitor.

Chenodeoxycholic Acid sodium salt (CDCA sodium salt) is a bile acid in humans that activates the nuclear receptor FXR, rescues axonal degeneration of induced pluripotent stem cell-derived neurons in patients with spastic paraplegia type 5 and cerebral xanthomatosis, and can be used to study pancreatic necrosis.

Megakaryocytes platelets inducing agent being useful in treating diseases involving thrombopenia. Megakaryocytes platelets inducing agent is an inducing agent for megakaryocytes and or platelets from pluripotent stem cells.

Neurodazine is a neural inducer that promotes the differentiation of pluripotent cells into neuronal cells.Neurodazine promotes differentiation by activating Wnt and Shh signaling.

OAC2 is an Oct4 activator which activates expression through the Oct4 gene promoter; enhances reprogramming efficiency by increasing the rate of production of induced pluripotent stem cells (iPSCs) from embryonic fibroblasts; an analog of OAC1.

OAC1 (BAS 00287861) is a compound activating Octamer-binding transcription factor 4 (Oct4). It enhances the iPSC reprogramming efficiency and accelerates the reprogramming process.

KY02111 facilitates differentiation of hPSCs to cardiomyocytes by inhibiting Wnt signaling, maybe affect downstream of GSK3β and APC.

MDI-114215 (compound 85) serves as an allosteric dual inhibitor of LIMK1 2 and exhibits favorable in vivo tolerance. It is capable of inhibiting the phosphorylation of cofilin in mouse brain region-induced pluripotent stem cells (iPSCs) and can be utilized in Fragile X Syndrome (FXS) research.

Smoothened (Smo) receptor agonist

promotes the reprogramming of human somatic cells to pluripotent stem cells

O4I2 is an effective Oct3 4 inducer in various human cell lines including human fibroblasts.

KP-1 is a selective fluorescent probe for labeling human pluripotent stem cells.

Neurodazole is a neurogenic inducer for converting pluripotent P19 cells into electrophysiologically active neurons.

Lipoxygenin is an inhibitor of 5-lipoxygenase (5-LO) with an IC50value of 5 μM for inhibition of 5-LO product synthesis in isolated human granulocytes stimulated with the cation ionophore A23187 .1It inhibits hedgehog-dependent signaling in Shh-LIGHT2 cells and TGF-β-, activin A-, bone morphogenic protein (BMP)-, or Wnt-dependent signaling in HEK293T cells (IC50s = 9.3, 3.2, 8.2, 9.6, and 3.7 μM, respectively, in luciferase reporter assays). Lipoxygenin (5 and 10 μM) increases levels of troponin T (TnnT), a marker of cardiomyocyte differentiation, in human induced pluripotent stem cells (iPSCs) stimulated with BMP4 and the glycogen synthase kinase 3 (GSK3) inhibitor CHIR99021 .

The methylation of lysine residues on histones plays a central role in determining euchromatin structure and gene expression. The histone methyltransferase (HMTase) G9a can mono- or dimethylate lysine 9 on histone 3 (H3), contributing to early embryogenesis, genomic imprinting, and lymphocyte development. BIX01294 (hydrochloride hydrate) is a selective inhibitor of G9a HMTase (IC50 = 1.7 μM). It less effectively inhibits the HMTase G9a-like protein (GLP; IC50 = 38 μM) and has no effect on other known HMTases. BIX01294 has been used in combination with the calcium channel activator BayK8644 to facilitate the generation of induced pluripotent stem cells from somatic cells in vitro.

PluriSIn #2 acts as a selective transcriptional inhibitor of topoisomerase II α (TOP2A) and effectively eliminates undifferentiated human pluripotent stem cells (hPSCs)[1].

CP21R7 (CP21) is an effective and specific GSK3β inhibitor. It is used as an activator of stem cells prior to the induction of differentiation of stem cells to smooth muscle and endothelial cells. CP21R7 can be combined with BMP4 to commit human pluripotent stem cells to a mesodermal fate.

TWS-119 is an inhibitor of glycogen synthase kinase-3β (GSK-3β) that induces neuronal differentiation in pluripotent murine embryonal carcinoma cells and embryonic stem cells (ESCs).

Eleclazine (GS-6615) is a novel and selective voltage-gated sodium channel inhibitor with antiarrhythmic properties that reduces peak sodium current (INaP) recorded from human induced pluripotent stem cell–derived cardiomyocytes.

CBB1007 trihydrochloride is a cell-permeable amidino-guanidinium compound that acts as a potent, reversible and substrate competitive LSD1 selective inhibitor (IC50 = 5.27 μM for hLSD1). IC50 Value: 5.27 uM Target: hLSD1 CBB1007 efficiently can block LSD1-mediated demethylation of H3K4Me2 and H3K4Me (IC50 ≤ 5 μM) with no effect on H3K4Me3 and H3K9Me2, and LSD2 and JARID1A activities. Increases H3K4Me2 and H3K4Me contents (IC50 ≤ 5 μM), and causes activation of epigenetically suppressed CHRM4 M4-ArchR and SCN3A genes in F9 cells (IC50 ≤ 3.74 μM). CBB1007 was Shown to preferentially arrest the growth of pluripotent tumors with minimal effect on non-pluripotent cancer or normal somatic cells (IC50 ≥ 100 μM).

CBB1007 HCl is a cell-permeable amidino-guanidinium compound identified as a potent, reversible, and substrate-competitive inhibitor of LSD1 (IC50 = 5.27 μM for hLSD1). It effectively inhibits LSD1-mediated demethylation of H3K4Me2 and H3K4Me (IC50 ≤ 5 μM), without affecting H3K4Me3 and H3K9Me2 demethylation, nor the activities of LSD2 and JARID1A. Moreover, CBB1007 increases the levels of H3K4Me2 and H3K4Me (IC50 ≤ 5 μM) and activates epigenetically suppressed genes CHRM4 M4-ArchR and SCN3A in F9 cells (IC50 ≤ 3.74 μM). It preferentially inhibits the growth of pluripotent tumors with minimal impact on non-pluripotent cancer or normal somatic cells (IC50 ≥ 100 μM).

N-Acetyl-Ser-Asp-Lys-Pro (Ac-SDKP) acetate, a specific substrate for the N-terminal active site of angiotensin-converting enzyme (ACE), functions as a natural inhibitor of pluripotent hematopoietic stem cell proliferation and exhibits anti-inflammatory and antifibrotic properties [1] [2].

Cyclo(RGDfC) TFA (Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA) is a cyclic pentapeptide, a cyclic RGD polypeptide with high affinity for αvβ3, which is capable of disrupting cellular integrin interactions. Cyclo(RGDfC) TFA inhibits pluripotent gene expression in embryonic stem cells (ESCs) and inhibits tumorigenic potential of mESCs in vivo. Cyclo(RGDfC) TFA inhibits the tumorigenic potential of mESC. Cyclo(RGDfC) TFA can be used for tumor-related studies.